Metacrine Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 10

Employees
  • Stock Symbol
  • MTCR

Stock Symbol
  • Share Price
  • $0.48

  • (As of Friday Closing)

Metacrine General Information

Description

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 4225 Executive Square
  • Suite 600
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Metacrine Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.48 $0.48 $0.30 - $0.68 $20.6M 42.6M 324K -$1.02

Metacrine Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (21,268) (22,654) 106,008
Revenue 0 0 0 0
EBITDA (36,100) (60,135) (35,855) (29,174)
Net Income (38,189) (62,207) (37,304) (28,933)
Total Assets 55,037 79,989 104,236 60,281
Total Debt 13,788 14,309 11,120 11,447
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Metacrine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Metacrine‘s full profile, request access.

Request a free trial

Metacrine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Metacrine‘s full profile, request access.

Request a free trial

Metacrine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapi
Pharmaceuticals
San Diego, CA
10 As of 2022
00000
000 0000-00-00
000000&0

000000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Morristown, NJ
000 As of 0000
00000
000000 - 000 00000

0000 0

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
000000000000000
Newton, MA
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Metacrine Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intercept(Biotechnology) Formerly VC-backed Morristown, NJ 000 00000 000000 - 000 00000
0000 000000000000 Formerly VC-backed Newton, MA 00 000.00 000000000 000.00
0000000 0000000000 Formerly VC-backed Newark, CA 00 00000 00000000 00000
00000000 Corporation Austin, TX 00 0000 00000000 0000
00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 43 competitors. Get the full list »

Metacrine Patents

Metacrine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021236648-A1 Crystalline forms of a farnesoid x receptor agonist Pending 18-Mar-2020 0000000000
CA-3171987-A1 Crystalline forms of a farnesoid x receptor agonist Pending 18-Mar-2020 0000000000
EP-4121010-A1 Crystalline forms of a farnesoid x receptor agonist Pending 18-Mar-2020 0000000000
EP-4121012-A1 Formulations of a farnesoid x receptor agonist Pending 18-Mar-2020 0000000000
AU-2021239956-A1 Formulations of a farnesoid x receptor agonist Pending 18-Mar-2020 A61K9/1635
To view Metacrine’s complete patent history, request access »

Metacrine Executive Team (15)

Name Title Board Seat Contact Info
Michael York Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Nicholas Smith Ph.D Senior Vice President, Chemistry
Theresa Lowry Executive Vice President Human Resources
Preston Klassen MD President and Chief Executive Officer
Richard Heyman Ph.D Co-Founder & Executive Chairman
You’re viewing 5 of 15 executive team members. Get the full list »

Metacrine Board Members (11)

Name Representing Role Since
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
Andrew Guggenhime Self Board Member 000 0000
Jeffrey Jonker JD Self Board Member 000 0000
John McHutchison MD Self Board Member 000 0000
Julia Owens Ph.D Metacrine Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Metacrine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metacrine Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Metacrine‘s full profile, request access.

Request a free trial

Metacrine ESG

Risk Overview

Risk Rating

Updated June, 10, 2021

32.71 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 947

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 427

Rank

00.00

Percentile

To view Metacrine’s complete esg history, request access »